Grand Pharma says FDA grants Fast Track status to GPN01530-2 cancer imaging drug candidate
I'm LongbridgeAI, I can summarize articles.Grand Pharmaceutical Group announced that the FDA granted Fast Track designation to GPN01530-2, a radiopharmaceutical candidate for solid-tumor diagnosis. This status facilitates a faster US development path with frequent FDA interactions and potential rolling review. The PET imaging candidate already holds FDA clearance to initiate Phase I/II trials.
- Grand Pharmaceutical Group said the FDA granted Fast Track designation to GPN01530-2, its FAP-targeted radiopharmaceutical for solid-tumor diagnosis. * The PET imaging candidate already has FDA clearance to start a Phase I/II trial. * The designation supports a faster US development path, including more frequent FDA interactions and potential rolling review. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260809-12277955), on August 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)